Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q1 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $740 thousand versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.